Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes
-
By
-
Santeri Palmi
-
Otso Arponen
-
Mika Murto
-
Aino Siltari
-
Arja Jukkola
-
Teemu Murtola
-
June 2, 2026
-
Clinical Scorecard: Impact of Statin Therapy on Survival Outcomes in Early-Stage Breast Cancer Across Various Intrinsic Subtypes
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Statins inhibit HMG-CoA reductase, reducing cholesterol biosynthesis. |
| Target Population | Female patients diagnosed with invasive breast cancer in Finland between 1995 and 2013. |
| Care Setting | |
Key Highlights
- Breast cancer is the most frequently diagnosed cancer and leading cause of cancer-related deaths in females globally.
- Statins inhibit HMG-CoA reductase, which may impact cell growth regulation.
Guideline-Based Recommendations
Diagnosis
- Breast cancer subtyping should be performed using immunohistochemical or in situ hybridization methods.
Management
- Statins are prescribed for cardiovascular disease prevention.
Monitoring & Follow-up
- Monitor cholesterol levels in breast cancer patients.
Risks
- Consider potential side effects of statins.
Patient & Prescribing Data
Female patients with early-stage breast cancer in Finland.
Statins are not available over the counter and are prescribed by physicians with partial reimbursement.
Clinical Best Practices
- Utilize data from national registries for patient management.
- Assess intrinsic subtypes for treatment approaches.
Related Resources & Content
